株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

スギ花粉アレルギー:パイプライン製品の分析

Cedar Pollen Allergy - Pipeline Review, H2 2017

発行 Global Markets Direct 商品コード 257823
出版日 ページ情報 英文 32 Pages
即納可能
価格
本日の銀行送金レート: 1USD=113.77円で換算しております。
Back to Top
スギ花粉アレルギー:パイプライン製品の分析 Cedar Pollen Allergy - Pipeline Review, H2 2017
出版日: 2017年09月19日 ページ情報: 英文 32 Pages
概要

スギアレルギーは、山間部の杉の木が発生させる花粉に対するアレルギー反応が原因の季節性アレルギーです。症状には、鼻水、目の痒み、涙目、鼻づまり、およびくしゃみなどが含まれます。患者の中には、疲労、軽い頭痛、顔面の不快感、咽頭痛、匂いの部分喪失、および耳づまりなども訴える人もいます。治療には抗ヒスタミン薬および充血除去剤(鼻炎薬)が用いられます。

当レポートでは、スギ花粉アレルギーに対する治療薬の開発状況について調査分析し、パイプライン製品の概要、治験の段階別の製品の概要、主要企業プロファイル、薬剤のプロファイルなどについて、体系的な情報を提供しています。

目次

イントロダクション

スギ花粉アレルギーの概要

治療薬の開発

  • パイプライン製品:概要
  • パイプライン製品:比較分析

開発中の治療薬:企業別

開発中の治療薬:大学/研究機関別

パイプライン製品の概要

  • 後期段階の製品
  • 臨床段階の製品
  • 初期段階の製品

開発中の製品:企業別

開発中の製品:大学/研究機関別

治療薬の開発に従事している企業

  • ALK-Abello A/S
  • Anergis SA
  • Circassia Pharmaceuticals Plc
  • Immunomic Therapeutics, Inc.
  • Japan Tobacco Inc.
  • REGiMMUNE Corporation

治療薬の評価

  • 単独療法の場合
  • 標的別
  • 投与経路別
  • 分子タイプ別

薬剤のプロファイル

  • AllerJ
  • ASP-4070
  • Drugs for Cedar Pollen Allergy
  • JCC-LAMP-Vax
  • MC-LAMP-Vax
  • RGI-1001
  • standardized mite (Dermatophagoides pteronyssinus + Dermatophagoides farinae) allergen vaccine
  • TO-206
  • Vaccine for Cedar Pollen Allergy
  • Vaccine for Japanese Cedar Pollen Allergy

パイプライン製品の最新動向

休止状態のプロジェクト

製品開発のマイルストーン

  • 注目すべき最新動向・プレスリリース

付録

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC9731IDB

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Cedar Pollen Allergy - Pipeline Review, H2 2017, provides an overview of the Cedar Pollen Allergy (Immunology) pipeline landscape.

Cedar allergy is a seasonal allergy brought on by an allergic reaction to the pollen from mountain cedar trees. Symptoms include runny nose, itchy and watery eyes, nasal blockage and sneezing. Some suffers also complain of fatigue, mild headache, facial discomfort, sore throat, partial loss of smell and the sensation of ear plugging. Treatment includes antihistamines and decongestants.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Cedar Pollen Allergy - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Cedar Pollen Allergy (Immunology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Cedar Pollen Allergy (Immunology) pipeline guide also reviews of key players involved in therapeutic development for Cedar Pollen Allergy and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase II and Preclinical stages are 1, 2 and 2 respectively. Similarly, the Universities portfolio in Phase II stages comprises 1 molecules, respectively.

Cedar Pollen Allergy (Immunology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Cedar Pollen Allergy (Immunology).
  • The pipeline guide reviews pipeline therapeutics for Cedar Pollen Allergy (Immunology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Cedar Pollen Allergy (Immunology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Cedar Pollen Allergy (Immunology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Cedar Pollen Allergy (Immunology)

Reasons to buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Cedar Pollen Allergy (Immunology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Cedar Pollen Allergy (Immunology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Cedar Pollen Allergy - Overview
    • Cedar Pollen Allergy - Therapeutics Development
    • Pipeline Overview
    • Pipeline by Companies
    • Pipeline by Universities/Institutes
    • Products under Development by Companies
    • Products under Development by Universities/Institutes
  • Cedar Pollen Allergy - Therapeutics Assessment
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Cedar Pollen Allergy - Companies Involved in Therapeutics Development
    • ALK-Abello A/S
    • Astellas Pharma Inc
    • Japan Tobacco Inc
    • REGiMMUNE Corp
    • Stallergenes Greer plc
  • Cedar Pollen Allergy - Drug Profiles
    • ASP-4070 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Biologic for Cedar Pollen Allergy - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • RGI-1001 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • STG-120 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • TO-206 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Vaccine for Cedar Pollen Allergy - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Cedar Pollen Allergy - Dormant Projects
  • Cedar Pollen Allergy - Discontinued Products
  • Cedar Pollen Allergy - Product Development Milestones
    • Featured News & Press Releases
      • Aug 07, 2015: ALK's partner for Japan reports positive Phase II/III trial results for Japanese Cedar SLIT-tablet
      • Mar 09, 2015: Immunomic Therapeutics to Present at BIO-Europe Annual Conference
      • Feb 20, 2015: Immunomic Therapeutics to Present Data on Its Proprietary LAMP Vaccine Platform at 2015 American Academy of Allergy, Asthma and Immunology Meeting
      • Apr 24, 2013: Immunomic Therapeutics Announces Interim Data Analysis Of Phase I Study To Treat Japanese Red Cedar Allergy
      • Nov 08, 2012: Immunomic Therapeutics Doses First Patient In Phase I Clinical Trial Of JRC-LAMP-Vax Vaccine To Treat Japanese Red Cedar Allergy
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development for Cedar Pollen Allergy, H2 2017
  • Number of Products under Development by Companies, H2 2017
  • Number of Products under Development by Universities/Institutes, H2 2017
  • Products under Development by Companies, H2 2017
  • Products under Development by Universities/Institutes, H2 2017
  • Number of Products by Stage and Route of Administration, H2 2017
  • Number of Products by Stage and Molecule Type, H2 2017
  • Cedar Pollen Allergy - Pipeline by ALK-Abello A/S, H2 2017
  • Cedar Pollen Allergy - Pipeline by Astellas Pharma Inc, H2 2017
  • Cedar Pollen Allergy - Pipeline by Japan Tobacco Inc, H2 2017
  • Cedar Pollen Allergy - Pipeline by REGiMMUNE Corp, H2 2017
  • Cedar Pollen Allergy - Pipeline by Stallergenes Greer plc, H2 2017
  • Cedar Pollen Allergy - Dormant Projects, H2 2017
  • Cedar Pollen Allergy - Discontinued Products, H2 2017

List of Figures

  • Number of Products under Development for Cedar Pollen Allergy, H2 2017
  • Number of Products under Development by Companies, H2 2017
  • Number of Products by Routes of Administration, H2 2017
  • Number of Products by Stage and Routes of Administration, H2 2017
  • Number of Products by Molecule Types, H2 2017
  • Number of Products by Stage and Molecule Types, H2 2017
Back to Top